Skip to content

Released Aug 9, 2024, after the close

10-Q filed Aug 9, 2024, 40 days after period end · 0000950170-24-094727

Q2 2024 · 10-Q
Revenue—
Net Income-$8.39MN/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$246.27N/M vs Q2 2023N/M vs Q1 2024
Operating Income-$2,522,397N/M
Operating Cash Flowderived-$2,478,682N/M
Free Cash Flowderived-$2,478,682N/M

What the release said

The release

Same quarter

MetricQ2 2024Q2 2023Q2 2022Q2 2021
Net Income-$8.39M-$1.45M-$1.83M-$2.47M
EPS Diluted-$246.27-$5.83-$4.16-$0.39

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Revelation Biosciences, Inc. · CIK 1810560 · Engraved from SEC EDGAR